Pyxis Oncology, Inc. Cash and Cash Equivalents
Pyxis Oncology, Inc. (PYXS) had Cash and Cash Equivalents of $18.86 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-13
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $18.86M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $5.77M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $15.42M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $8.92M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2026-06-30 | $18.86M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $5.77M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $15.42M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $8.92M 10-Q · filed 2025-11-03 |
| 2025-06-30 | $10.73M 10-Q · filed 2026-08-13 |
| 2025-03-31 | $12.76M 10-Q · filed 2026-05-14 |
| 2024-12-31 | $19.47M 10-K · filed 2026-03-23 |
| 2024-09-30 | $12.06M 10-Q · filed 2025-11-03 |
| 2024-06-30 | $25.07M 10-Q · filed 2025-08-14 |
| 2024-03-31 | $27.97M 10-Q · filed 2025-05-15 |
| 2023-12-31 | $9.66M 10-K · filed 2025-03-18 |
| 2023-09-30 | $14.71M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $25.90M 10-Q · filed 2024-08-14 |
| 2023-03-31 | $53.06M 10-Q · filed 2024-05-14 |
| 2022-12-31 | $179.29M 10-K · filed 2024-03-21 |
| 2022-09-30 | $198.54M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $223.35M 10-Q · filed 2023-08-11 |
| 2022-03-31 | $247.09M 10-Q · filed 2023-05-11 |
| 2021-12-31 | $274.74M 10-K · filed 2023-03-22 |
| 2021-09-30 | $133.48M 10-Q · filed 2022-11-01 |
| 2021-06-30 | $142.47M 10-Q · filed 2022-08-15 |
| 2021-03-31 | $140.66M 10-Q · filed 2022-05-13 |
| 2020-12-31 | $8.08M 10-K · filed 2022-03-29 |
| 2020-09-30 | $11.25M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |